Skip to main content
OpenTrials
Completed

NCT Number: NCT05162183

Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Brigham and Women's Hospital

Boston, Massachusetts, 02135, United States

About this study

This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates through standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Type 2 Diabetes mellitus [0,0] days
  • 3 or more recorded HbA1c values [-365, 0] days
  • At least two dispensing claims for metformin [-180,0] days
  • 1 or more recorded HbA1c values [-90,0] days
  • Age between 18-80 [0,0] days

Exclusion criteria

  • Cancer, malignant neoplasm, or MEN2 [-1,825,0] days
  • Use of other anti-diabetic medications [-180,0] days
  • Cirrhosis or Hepatic decompensation [-180,0] days
  • Viral hepatitis B or C [-180,0] days
  • Stage 5 CKD, ESRD, dialysis or renal transplant [-180,0] days
  • MI or HF [-180,0] days
  • Treatment with Anti-VEGFi or Photocoagulation [-180,0] days
  • Hypertensive crisis or uncontrolled hypertension [-180,0] days
  • Two diagnoses of hypoglycemia [-180,0] days
  • Alcohol/drug abuse/dependence [-180,0] days
  • Dementia and brain damages or non-compliance [-180,0] days
  • Pregnancy [-180,0] days
  • Type 1 DM, DKA, or other metabolic acidosis [-180,0] days
  • Systemic corticosteroids [-90,0] days

Treatment and study plan

Glimepiride

Drug

Glimepiride dispensing claim is used as the reference group.

liraglutide

Drug

Liraglutide dispensing claim is used as the exposure group.

Primary outcomes

  1. Relative Hazard of change in HbA1c from baseline to 26 weeks of treatment (end of follow-up)

    Time frame: 26-week follow-up window with a median follow-up time of 99 [84, 148] days

    Claims-based algorithm: relative hazard of change in HbA1c from baseline to 26 weeks of treatment (end of follow-up)

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Registry information

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Dec 17, 2021
Registry last updated
Jul 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.